Actively Recruiting
Investigation of Long-term Outcomes and Risk Factors in Patients With Hepatitis B Related Acute-on-chronic Liver Failure
Led by Third Affiliated Hospital, Sun Yat-Sen University · Updated on 2024-11-29
300
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the long-term outcomes and factors that affect prognosis in patients who have recovered from hepatitis B virus related acute-on-chronic liver failure (ACLF). This condition involves sudden liver failure on top of chronic liver disease, mainly caused by hepatitis B virus infection in China. Previous studies focused on short-term survival, but this research aims to better understand the long-term health of patients after spontaneous recovery from this condition. The study retrospectively reviews clinical data of patients with hepatitis B associated ACLF admitted to the infectious diseases department at the Third Affiliated Hospital of Sun Yat-Sen University. It includes a telephone follow-up survey to investigate their long-term prognosis. There are no intervention treatments or study drugs, as this is an observational study focused on monitoring outcomes over time. Participants will be observed for adverse events over a period of five years. Researchers analyze clinical events and survival data collected during hospitalization as well as follow-up information gathered by phone. The study aims to identify risk factors that influence long-term survival and health status in these patients, helping to improve understanding and management of hepatitis B related ACLF.
CONDITIONS
Brief Title
Long-term Prognosis of Patients With Hepatitis B Related Acute-on-chronic Liver Failure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age from 18 to 65 years old
- Diagnosis consistent with hepatitis B associated chronic acute liver failure
- Survival time more than 90 days after hospitalization
- Complete inpatient clinical data available
You will not qualify if you...
- Human immunodeficiency virus infection or congenital immune deficiency diseases
- Liver cancer, other tumors, autoimmune liver disease, genetic or metabolic liver disease, or other serious diseases that significantly affect survival
- Other conditions judged by researchers as inappropriate for inclusion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 5 years
Participants are observed over an extended period to assess clinical events and long-term prognosis related to hepatitis B associated acute on chronic liver failure.
Telephone follow-up surveys
Trial Site Locations
Total: 1 location
1
Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 510630
Actively Recruiting
Research Team
L
Lu Wang, Doctor
L
Liang Peng, Doctor
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here